PrecipioPRPO
PRPO
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
11% more funds holding
Funds holding: 9 [Q3] → 10 (+1) [Q4]
0.7% more ownership
Funds ownership: 4.24% [Q3] → 4.94% (+0.7%) [Q4]
5% less capital invested
Capital invested by funds: $422K [Q3] → $402K (-$20.5K) [Q4]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for PRPO.
Financial journalist opinion
Neutral
Seeking Alpha
16 hours ago
Precipio, Inc. (PRPO) Q4 2024 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Conference Call Participants Operator Welcome to the Precipio Q4 and Year-End 2024 Shareholder Update Conference Call. All participants will be in listen-only mode.

Neutral
GlobeNewsWire
2 weeks ago
Precipio Announces Q4 and year-end 2024 Shareholder Update Call
NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET.

Neutral
GlobeNewsWire
1 month ago
Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)
Both metrics demonstrate the ability to achieve financial independence Both metrics demonstrate the ability to achieve financial independence

Neutral
GlobeNewsWire
2 months ago
Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs
NEW HAVEN, Conn., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announced that options granted to senior management on January 14 would vest when the 10-day VWAP of the Company's common stock exceeds $30.30 per share – a level 5x greater than the option exercise price, the closing price from Tuesday, January 14.

Positive
Zacks Investment Research
4 months ago
Two Smaller Companies Worthy of Your "Attention"
Here we highlight a small cap and a microcap with Zacks Outperform ratings.

Neutral
Seeking Alpha
4 months ago
Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q3 2024 Earnings Conference Call November 18, 2024 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Good day. Welcome to the Precipio Third Quarter 2024 Shareholder Update Conference Call.

Neutral
GlobeNewsWire
4 months ago
Precipio Announces Q3-2024 Shareholder Update Call
NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses.

Neutral
GlobeNewsWire
5 months ago
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients

Neutral
GlobeNewsWire
6 months ago
Precipio Announces Employee Stock Option Plan Repricing
NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees.

Positive
Zacks Investment Research
6 months ago
Zacks Initiates Coverage of Precipio With Outperform Recommendation
Discover why Zacks rates Precipio as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore PRPO's approaching breakeven milestones, financial health, and market positioning in the cancer diagnostics space.

Charts implemented using Lightweight Charts™